Classifying risk factors for dyskinesia in Parkinson's disease

被引:82
|
作者
Sharma, J. C. [1 ]
Bachmann, C. G. [2 ]
Linazasoro, G. [3 ]
机构
[1] Univ Nottingham, Sherwood Forest Hosp NHS Trust, Nottingham NG7 2RD, England
[2] Univ Gottingen, Dept Clin Neurophysiol, Gottingen, Germany
[3] Fdn Inbiomed, Policlin Gipuzkoa, Ctr Invest Parkinson, San Sebastian, Spain
关键词
Dyskinesia; Levodopa dose per kilogram body weight; Risk factors; Parkinson's disease; LEVODOPA-INDUCED DYSKINESIAS; RECEPTOR GENE POLYMORPHISM; MOTOR FLUCTUATIONS; L-DOPA; BODY-WEIGHT; ONSET AGE; MOLECULAR-MECHANISMS; CLINICAL-FEATURES; ASSOCIATION; THERAPY;
D O I
10.1016/j.parkreldis.2010.06.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Currently there is no classification of risk factors applicable to an individual patient with Parkinson's disease for the development of dyskinesia. Methods: We conducted literature search to identify and classifying risk factors into groups (a) intrinsic vs extrinsic and (b) modifiable vs non-modifiable. Results: Younger age, young age of onset and severity of PD are major intrinsic non-modifiable risk factors for dyskinesia, female gender is another factor but not independent of other factors. Genetic expression and plasticity may determine pre-disposition to age of onset of PD and dyskinesia, these are currently non-modifiable factors arising due to an interaction of intrinsic and extrinsic factors. Lower initial body weight and weight loss during the course of the disease increase the risk of dyskinesia. Levodopa dose per kilogram body weight is a more significant risk factor than absolute levodopa dose. Early use of longer acting non-levodopa (i.e. dopamine agonists) medications delays the onset of dyskinesia. Interaction between body weight, levodopa dose and mode and duration of drug delivery is a significant modifiable factor. Conclusion: Dyskinesia in PD arises as a consequence of the interaction of intrinsic versus extrinsic and modifiable versus non-modifiable factors. Identification and manipulation of modifiable factors for an individual patient may reduce the risk and burden of dyskinesia. Adjustment of levodopa dose according to body weight during the course of the disease seems to be a significant modifiable risk factor for dyskinesia. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:490 / 497
页数:8
相关论文
共 50 条
  • [31] Occupational risk factors in Parkinson's disease
    Tsui, JKC
    Calne, DB
    Wang, Y
    Schulzer, M
    Marion, SA
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 1999, 90 (05): : 334 - 337
  • [32] RISK FACTORS OF DEVELOPING PARKINSON'S DISEASE
    Turaeva, G.
    Tursunov, D.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E41 - E41
  • [33] Risk factors for hallucinations in Parkinson's disease
    Paleacu, D.
    Schechtman, E.
    Inzelberg, R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 308 - 308
  • [34] Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease
    Nicoletti, Alessandra
    Mostile, Giovanni
    Nicoletti, Giuseppe
    Arabia, Gennarina
    Iliceto, Giovanni
    Lamberti, Paolo
    Marconi, Roberto
    Morgante, Letterio
    Barone, Paolo
    Quattrone, Aldo
    Zappia, Mario
    JOURNAL OF NEUROLOGY, 2016, 263 (05) : 888 - 894
  • [35] Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease
    Alessandra Nicoletti
    Giovanni Mostile
    Giuseppe Nicoletti
    Gennarina Arabia
    Giovanni Iliceto
    Paolo Lamberti
    Roberto Marconi
    Letterio Morgante
    Paolo Barone
    Aldo Quattrone
    Mario Zappia
    Journal of Neurology, 2016, 263 : 888 - 894
  • [36] Swallowing abnormalities and dyskinesia in Parkinson's disease
    Monte, FS
    da Silva-Júnior, FP
    Braga-Neto, P
    Souza, MANE
    de Bruin, VMS
    MOVEMENT DISORDERS, 2005, 20 (04) : 457 - 462
  • [37] Patient perception of dyskinesia in Parkinson's disease
    Hung, S. W.
    Adeli, G. M.
    Arenovich, T.
    Fox, S. H.
    Lang, A. E.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (10): : 1112 - 1115
  • [38] Lamotrigine induced dyskinesia in Parkinson's disease
    Sabolek, M.
    Runge, U.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (05) : e37 - e37
  • [39] Rhabdomyolysis Related to Dyskinesia in Parkinson's Disease
    Bektas, Hesna
    Deniz, Orhan
    Temel, Sadiye
    Keklikoglu, Hava Donmez
    Akyol, Sener
    JOURNAL OF MOVEMENT DISORDERS, 2014, 7 (01) : 25 - 27
  • [40] Memantine reduces dyskinesia in Parkinson's disease
    Wictorin, K.
    Widner, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 137 - 138